MAGDALENA DEATON: Open Payments
NPI 1285281303 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$986 in 48 payments from 12 companies in 2025. Trend: 2023 $57 · 2024 $509 · 2025 $986
Food & beverage: $968Education: $17
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 23 | $428 |
| Verona Pharma, Inc. | 5 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $82 |
| GENZYME CORPORATION | 3 | $73 |
| Regeneron Healthcare Solutions, Inc. | 3 | $72 |
| Viatris Specialty LLC | 3 | $57 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $43 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $29 |
| AstraZeneca Pharmaceuticals LP | 1 | $27 |
Products named: NUCALA, TRELEGY ELLIPTA, DUPIXENT, Ohtuvayre, ARALAST, YUPELRI, OFEV, OPSUMIT.
Industry payments across TX — which companies pay providers there.
